soul trial oral semaglutide cardiovascular outcomes results 2025 (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine New in the May 29,

Surprising Fact The weight loss drug Wegovy could lower the risk of adverse cardiovascular events by 20%, according to data from a trial shared by Novo Nordisk in August

Tirzepatide may contribute to low blood pressure in some situations, especially if blood pressure is already being treated with medication or if a person becomes dehydrated

1, 3 6 Although most frequently the chest, shoulder or upper arm are involved, examples have occurred everywhere on the skin surface

Going from 2.5 mg to 5 mg is a 100% dose increase

The winners of this movement will be the brands that successfully engineer satisfaction in smaller formats and let guests choose for themselves

Restrain/Challenge Complex Regulatory Requirements and Development Costs One of the key constraints faced by the global GLP-1 drug biosimilar market is that related to complexity in the development and approval process for biosimilars